Zoetis Company Profile (NYSE:ZTS)

About Zoetis (NYSE:ZTS)

Zoetis logoZoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Veterinary Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ZTS
  • CUSIP: 98978V10
  • Web: www.zoetis.com
  • Market Cap: $30.99873 billion
  • Outstanding Shares: 490,796,000
Average Prices:
  • 50 Day Moving Avg: $62.65
  • 200 Day Moving Avg: $57.14
  • 52 Week Range: $46.86 - $63.85
  • Trailing P/E Ratio: 36.72
  • Foreward P/E Ratio: 23.62
  • P/E Growth: 2.10
Sales & Book Value:
  • Annual Revenue: $4.96 billion
  • Price / Sales: 6.26
  • Book Value: $3.28 per share
  • Price / Book: 19.30
  • Annual Dividend: $0.42
  • Dividend Yield: 0.7%
  • EBIDTA: $1.71 billion
  • Net Margins: 17.25%
  • Return on Equity: 65.35%
  • Return on Assets: 13.06%
  • Debt-to-Equity Ratio: 2.27%
  • Current Ratio: 1.96%
  • Quick Ratio: 1.07%
  • Average Volume: 2.79 million shs.
  • Beta: 1.03
  • Short Ratio: 3.82
Frequently Asked Questions for Zoetis (NYSE:ZTS)

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Friday, May 12th. Investors of record on Thursday, June 15th will be given a dividend of $0.105 per share on Friday, September 1st. This represents a $0.42 annualized dividend and a yield of 0.66%. The ex-dividend date of this dividend is Tuesday, June 13th. View Zoetis' Dividend History.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings data on Thursday, May, 4th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.05. The business earned $1.23 billion during the quarter, compared to analysts' expectations of $1.20 billion. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. The company's revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.48 earnings per share. View Zoetis' Earnings History.

When will Zoetis make its next earnings announcement?

Zoetis is scheduled to release their next quarterly earnings announcement on Tuesday, August, 8th 2017. View Earnings Estimates for Zoetis.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY17 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $2.26-2.36 for the period, compared to the Thomson Reuters consensus estimate of $2.32. The company issued revenue guidance of $5.10-5.225 billion, compared to the consensus revenue estimate of $5.17 billion.

Where is Zoetis' stock going? Where will Zoetis' stock price be in 2017?

18 brokerages have issued 1 year price targets for Zoetis' stock. Their forecasts range from $35.00 to $77.00. On average, they expect Zoetis' stock price to reach $63.06 in the next twelve months. View Analyst Ratings for Zoetis.

What are analysts saying about Zoetis stock?

Here are some recent quotes from research analysts about Zoetis stock:

  • 1. According to Zacks Investment Research, "Zoetis’ growth in revenues is being driven by sales of companion animal products such as Simparica, Apoquel and Cytopoint while the livestock portfolio was driven by growth in swine, cattle and fish across the international markets. Zoetis’ expects to see stronger growth from its companion animal portfolio in 2017 driven by Apoquel and Cytopoint, further penetration of Simparica, and ongoing uptake of new vaccines. Favorable market conditions contributed to swine performance in China as well as cattle product sales in Brazil. Shares of Zoetis have outperformed the industry in 2017 so far. However, disease outbreak among animals is a material cause of concern for Zoetis’ livestock products. Zoetis faces stiff competition from companies like Merck Animal Health (the animal health division of Merck), Elanco (the animal health division of Eli Lilly among others. " (7/4/2017)
  • 2. Guggenheim analysts commented, "We are raising our PT for ZTS shares after a 4Q beat and a lower than expected FX headwind for '17. The increase in our PT is driven by multiple expansion. We arrive at our new PT by using a DCF analysis. ZTS's solid execution this quarter increases our confidence that it can exceed consensus expectations for '17+ and sustain its 21x forward P/E multiple. Upward earnings revisions could come from margin expansion, M&A, and launches. Therefore, the sell-off today, which we think is motivated by profit taking, is overdone, in our view. We believe the weakness (ZTS down 3% vs. S&P down 0.14%) presents a good buying opportunity for the stock." (2/16/2017)

Who are some of Zoetis' key competitors?

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:

  • Juan Ramon Alaix, Chief Executive Officer, Director
  • Glenn David, Chief Financial Officer, Executive Vice President
  • Roxanne Lagano, Chief Human Resource Officer, Executive Vice President
  • Andrew Fenton, Executive Vice President, Chief Information Officer
  • Heidi C. Chen, Executive Vice President, General Counsel, Corporate Secretary
  • Alejandro Bernal, Executive Vice President, Group President - Strategy, Commercial and Business Development
  • Catherine A. Knupp, Executive Vice President, President - Research and Development
  • Clinton A. Lewis Jr., Executive Vice President, President - International Operations
  • Kristin C. Peck, Executive Vice President, President - U.S. Operations
  • Roman Trawicki, Executive Vice President, President of Global Manufacturing and Supply

Who owns Zoetis stock?

Zoetis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Treasurer State of Michigan (0.32%), AMF Pensionsforsakring AB (0.20%), Atalanta Sosnoff Capital LLC (0.15%), AMI Asset Management Corp (0.13%), Vontobel Asset Management Inc. (0.12%) and Bank of Montreal Can (0.11%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck, Michael B Mccallister, Pershing Square Capital Manage and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.

Who sold Zoetis stock? Who is selling Zoetis stock?

Zoetis' stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Atalanta Sosnoff Capital LLC, Boussard & Gavaudan Investment Management LLP, Copeland Capital Management LLC, Quantitative Systematic Strategies LLC, AMI Asset Management Corp, Exxonmobil Investment Management Inc. TX and Daiwa SB Investments Ltd.. Company insiders that have sold Zoetis stock in the last year include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck and Roxanne Lagano. View Insider Buying and Selling for Zoetis.

Who bought Zoetis stock? Who is buying Zoetis stock?

Zoetis' stock was purchased by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, State Treasurer State of Michigan, Hermes Investment Management Ltd., Mn Services Vermogensbeheer B.V., Gladstone Capital Management LLP, US Bancorp DE, OLD National Bancorp IN and Bank of Montreal Can. View Insider Buying and Selling for Zoetis.

How do I buy Zoetis stock?

Shares of Zoetis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of Zoetis stock can currently be purchased for approximately $63.29.

MarketBeat Community Rating for Zoetis (NYSE ZTS)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  400 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  610
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Zoetis (NYSE:ZTS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $63.06 (0.37% downside)

Analysts' Ratings History for Zoetis (NYSE:ZTS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Stifel NicolausReiterated RatingBuy$65.00LowView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingBuy$62.00 -> $65.00LowView Rating Details
7/17/2017Cowen and CompanySet Price TargetBuy$70.00LowView Rating Details
6/20/2017Hilliard LyonsInitiated CoverageBuy$77.00LowView Rating Details
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$75.00LowView Rating Details
6/13/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$64.00 -> $65.00LowView Rating Details
5/30/2017ArgusReiterated RatingBuy$60.00 -> $69.00LowView Rating Details
5/26/2017CL KingInitiated CoverageBuy -> Buy$71.00LowView Rating Details
5/24/2017Credit Suisse GroupBoost Price TargetOutperform$61.00 -> $67.00LowView Rating Details
5/9/2017Jefferies Group LLCBoost Price TargetBuy$65.00 -> $70.00LowView Rating Details
3/15/2017Craig HallumInitiated CoverageBuy$65.00LowView Rating Details
2/16/2017GuggenheimBoost Price TargetBuy$60.00 -> $65.00N/AView Rating Details
2/16/2017Off Wall StreetReiterated RatingStrong Sell$35.00N/AView Rating Details
12/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$61.00N/AView Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingHold$53.00N/AView Rating Details
9/29/2016Bank of America CorporationInitiated CoverageBuy$60.00N/AView Rating Details
8/4/2016Citigroup Inc.Boost Price TargetNeutral$50.00 -> $53.00N/AView Rating Details
8/4/2016Barclays PLCBoost Price TargetEqual Weight$45.00 -> $49.00N/AView Rating Details
5/6/2016Goldman Sachs Group, Inc. (The)DowngradeNeutral -> Sell$46.00 -> $48.00N/AView Rating Details
1/8/2016Cleveland ResearchInitiated CoverageBuyN/AView Rating Details
8/6/2015William BlairUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Zoetis (NYSE:ZTS)
Earnings by Quarter for Zoetis (NYSE:ZTS)
Earnings History by Quarter for Zoetis (NYSE ZTS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017$0.53N/AView Earnings Details
5/4/2017Q1 2017$0.48$0.53$1.20 billion$1.23 billionViewListenView Earnings Details
2/16/2017Q416$0.45$0.47$1.28 billion$1.30 billionViewN/AView Earnings Details
11/2/2016Q316$0.46$0.52$1.22 billion$1.20 billionViewN/AView Earnings Details
8/3/2016Q216$0.44$0.49$1.17 billion$1.20 billionViewN/AView Earnings Details
5/4/2016Q116$0.41$0.48$1.10 billion$1.20 billionViewN/AView Earnings Details
2/16/2016Q415$0.39$0.43$1.25 billion$1.30 billionViewListenView Earnings Details
11/3/2015Q315$0.40$0.50$1.18 billion$1.20 billionViewN/AView Earnings Details
8/4/2015Q215$0.38$0.43$1.12 billion$1.20 billionViewN/AView Earnings Details
5/5/2015Q115$0.37$0.41$1.11 billion$1.10 billionViewN/AView Earnings Details
2/11/2015Q414$0.36$0.40$1.27 billion$1.30 billionViewN/AView Earnings Details
11/4/2014Q314$0.37$0.41$1.16 billion$1.20 billionViewN/AView Earnings Details
5/6/2014Q114$0.37$0.38$1.13 billion$1.10 billionViewN/AView Earnings Details
2/11/2014Q413$0.34$0.36$1.21 billion$1.25 billionViewN/AView Earnings Details
11/5/2013Q313$0.34$0.34$1.07 billion$1.10 billionViewN/AView Earnings Details
8/6/2013Q2 2013$0.36$0.36$1.13 billion$1.11 billionViewN/AView Earnings Details
4/30/2013Q1 2013$0.27$0.36$1.24 billion$1.09 billionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Zoetis (NYSE:ZTS)
2017 EPS Consensus Estimate: $2.25
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.47$0.49$0.48
Q2 20171$0.50$0.50$0.50
Q3 20171$0.62$0.62$0.62
Q4 20171$0.65$0.65$0.65
(Data provided by Zacks Investment Research)


Current Dividend Information for Zoetis (NYSE:ZTS)
Next Dividend:9/1/2017
Annual Dividend:$0.42
Dividend Yield:0.66%
Dividend Growth:24.90% (3 Year Average)
Payout Ratio:24.42% (Trailing 12 Months of Earnings)
18.03% (Based on This Year's Estimates)
15.67% (Based on Next Year's Estimates)
Track Record:3 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Zoetis (NYSE:ZTS)

Dividend History by Quarter for Zoetis (NYSE ZTS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Zoetis (NYSE:ZTS)
Insider Ownership Percentage: 0.31%
Institutional Ownership Percentage: 95.20%
Insider Trades by Quarter for Zoetis (NYSE:ZTS)
Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)
Insider Trades by Quarter for Zoetis (NYSE:ZTS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Catherine A KnuppInsiderSell5,785$60.16$348,025.60View SEC Filing  
11/22/2016Kristin C PeckInsiderSell10,092$49.55$500,058.60View SEC Filing  
11/8/2016Roxanne LaganoInsiderSell9,797$50.43$494,062.71View SEC Filing  
9/6/2016Michael B MccallisterDirectorBuy2,000$51.34$102,680.00View SEC Filing  
9/2/2016Andrew FentonInsiderSell13,870$51.25$710,837.50View SEC Filing  
9/1/2016Heidi C ChenInsiderSell32,097$50.98$1,636,305.06View SEC Filing  
5/9/2016Pershing Square Capital ManageDirectorSell16,850,000$46.55$784,367,500.00View SEC Filing  
8/8/2013Michael MccallisterDirectorBuy7,000$31.35$219,450.00View SEC Filing  
2/6/2013Frank A DamelioDirectorBuy5,000$26.00$130,000.00View SEC Filing  
2/6/2013Sandra J BeatyEVPBuy2,000$26.00$52,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Zoetis (NYSE:ZTS)
Latest Headlines for Zoetis (NYSE:ZTS)
americanbankingnews.com logoZoetis (NYSE:ZTS) & Aratana Therapeutics (PETX) Financial Review
www.americanbankingnews.com - July 24 at 10:19 PM
americanbankingnews.com logoZoetis Inc. (NYSE:ZTS) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - July 21 at 4:52 PM
americanbankingnews.com logoZoetis Inc. (ZTS) Price Target Increased to $65.00 by Analysts at Deutsche Bank AG
www.americanbankingnews.com - July 17 at 5:58 PM
finance.yahoo.com logoETFs with exposure to Zoetis, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 8:39 PM
seekingalpha.com logoKindred Biosciences: Up 100% YTD With Even Greater Potential In H2
seekingalpha.com - July 13 at 11:35 AM
americanbankingnews.com logoZoetis Inc. (NYSE:ZTS) Expected to Post Earnings of $0.53 Per Share
www.americanbankingnews.com - July 12 at 10:40 PM
finance.yahoo.com logoPerformance of Zoetis Stock in 2Q17
finance.yahoo.com - July 11 at 9:56 AM
americanbankingnews.com logoZoetis Inc. (ZTS) Expected to Post FY2017 Earnings of $2.26 Per Share
www.americanbankingnews.com - July 6 at 8:00 AM
americanbankingnews.com logoZoetis Inc. (NYSE:ZTS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 4 at 5:22 PM
americanbankingnews.com logoZacks Investment Research Lowers Zoetis Inc. (NYSE:ZTS) to Hold
www.americanbankingnews.com - July 4 at 1:04 PM
americanbankingnews.com logoCritical Review: Aratana Therapeutics (PETX) versus Zoetis (ZTS)
www.americanbankingnews.com - July 2 at 4:34 PM
finance.yahoo.com logoZoetis to Host Webcast and Conference Call on Second Quarter 2017 Financial Results
finance.yahoo.com - July 1 at 9:23 AM
finance.yahoo.com logoETFs with exposure to Zoetis, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 9:23 AM
americanbankingnews.com logoPhibro Animal Health Corporation (PAHC) vs. Zoetis (ZTS) Critical Review
www.americanbankingnews.com - June 29 at 10:49 AM
finance.yahoo.com logoCramer's lightning round: Don't go down the food chain in this space
finance.yahoo.com - June 22 at 7:59 PM
streetinsider.com logoHilliard Lyons Reinstates Zoetis Inc. (ZTS) at Buy, "A Top Operator in an Industry with Solid Secular Growth" - StreetInsider.com
www.streetinsider.com - June 22 at 2:57 PM
americanbankingnews.com logoCritical Review: Zoetis (ZTS) and Phibro Animal Health Corporation (PAHC)
www.americanbankingnews.com - June 21 at 10:20 AM
americanbankingnews.com logoZoetis Inc. (ZTS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - June 20 at 4:10 PM
finance.yahoo.com logoETFs with exposure to Zoetis, Inc. : June 20, 2017
finance.yahoo.com - June 20 at 3:48 PM
finance.yahoo.com logoZoetis, Inc. :ZTS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 20 at 9:29 AM
americanbankingnews.com logoZoetis Inc. (ZTS) Now Covered by Analysts at Hilliard Lyons
www.americanbankingnews.com - June 20 at 9:21 AM
americanbankingnews.com logo$1.25 Billion in Sales Expected for Zoetis Inc. (ZTS) This Quarter
www.americanbankingnews.com - June 18 at 8:14 AM
americanbankingnews.com logoZoetis Inc. (ZTS) Now Covered by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 17 at 10:28 AM
americanbankingnews.com logoZoetis Inc. (ZTS) Expected to Post Earnings of $0.53 Per Share
www.americanbankingnews.com - June 16 at 10:22 PM
streetinsider.com logoUPDATE: Cantor Fitzgerald Starts Zoetis Inc. (ZTS) at Overweight, Sees Upside To EPS Estimates From M&A Among ... - StreetInsider.com
www.streetinsider.com - June 16 at 2:24 AM
finance.yahoo.com logoZoetis, Inc. : ZTS-US: Dividend Analysis : June 15th, 2017 (record date) : By the numbers : June 15, 2017
finance.yahoo.com - June 15 at 4:19 PM
streetinsider.com logoBMO Capital Downgrades Zoetis Inc. (ZTS) to Market Perform
www.streetinsider.com - June 14 at 9:34 PM
finance.yahoo.com logoLooking For A Better Entry Point, BMO Downgrades Zoetis Shares
finance.yahoo.com - June 14 at 2:32 AM
americanbankingnews.com logoZoetis Inc. (ZTS) Downgraded by BMO Capital Markets to "Market Perform"
www.americanbankingnews.com - June 13 at 8:28 AM
finance.yahoo.com logoZoetis Stock Is Sizzling Hot -- Here's What Could Make It Cool Down
finance.yahoo.com - June 11 at 8:34 AM
fool.com logoZoetis Stock Is Sizzling Hot -- Here's What Could Make It Cool Down
www.fool.com - June 11 at 7:32 AM
americanbankingnews.com logoZoetis Inc (ZTS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 9 at 4:32 PM
finance.yahoo.com logoZoetis (ZTS) Up 6.4% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 9 at 3:12 AM
fool.com logoZoetis Just Hit an All-Time High: Here's Why the Stock Should Go Higher
www.fool.com - June 3 at 12:49 PM
finance.yahoo.com logoZoetis to Participate in the William Blair Growth Stock Conference
finance.yahoo.com - June 2 at 8:19 AM
americanbankingnews.com logoArgus Reiterates Buy Rating for Zoetis Inc (ZTS)
www.americanbankingnews.com - May 30 at 1:51 PM
nasdaq.com logoZoetis Reaches Analyst Target Price
www.nasdaq.com - May 26 at 9:11 AM
finance.yahoo.com logoZoetis to Participate in the Stifel 2017 Dental and Veterinary Conference
finance.yahoo.com - May 26 at 9:11 AM
americanbankingnews.com logoZoetis Inc (ZTS) Research Coverage Started at CL King
www.americanbankingnews.com - May 26 at 9:04 AM
finance.yahoo.com logoHorizon (HZNP) Sells European Rights for Procysbi & Quinsair
finance.yahoo.com - May 25 at 8:13 AM
americanbankingnews.com logoCredit Suisse Group AG Reiterates Outperform Rating for Zoetis Inc (ZTS)
www.americanbankingnews.com - May 24 at 9:34 PM
streetinsider.com logoZoetis (ZTS): Raising PT - Credit Suisse - StreetInsider.com
www.streetinsider.com - May 24 at 8:00 AM
finance.yahoo.com logoCelgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
finance.yahoo.com - May 23 at 8:14 PM
fool.com logoCan These 3 High-Flying Healthcare Stocks Reach the Clouds?
www.fool.com - May 23 at 3:22 PM
fool.com logo3 Top Animal-Health Companies to Buy in 2017
www.fool.com - May 21 at 3:20 PM
finance.yahoo.com logoWhat’s Really Driving Zoetis’s Margins in 2017?
finance.yahoo.com - May 19 at 1:57 PM
finance.yahoo.com logoInside Zoetis’s Growth Strategy in 2017
finance.yahoo.com - May 19 at 1:57 PM
finance.yahoo.com logoBehind Zoetis’s Multi-Pronged Strategy to Strengthen Its Product Portfolio
finance.yahoo.com - May 18 at 8:15 AM
finance.yahoo.com logoInside Zoetis’s Key Revenue Drivers
finance.yahoo.com - May 17 at 11:42 PM
finance.yahoo.com logoWhy Zoetis’s Apoquel and Cytopoint Are Expected to Report Robust Revenues
finance.yahoo.com - May 17 at 11:42 PM



Zoetis (ZTS) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff